Inflammation and dysregulated lipid metabolism are important features of HGPS, implying that strategies to regulate CD36 protein and the NF‐kB pathway may be potential HGPS drug targets warranting further investigation to alleviate the inflammation and tissue damage. The gene discussed is NFKB1; the disease is Hutchinson-Gilford progeria syndrome.